LivaNova PLC (LIVN) - Net Assets
Based on the latest financial reports, LivaNova PLC (LIVN) has net assets worth $1.33 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.64 Billion) and total liabilities ($1.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LIVN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.33 Billion |
| % of Total Assets | 50.19% |
| Annual Growth Rate | 12.57% |
| 5-Year Change | -7.31% |
| 10-Year Change | -29.7% |
| Growth Volatility | 568.79 |
LivaNova PLC - Net Assets Trend (1992–2025)
This chart illustrates how LivaNova PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see LIVN stock market capitalisation.
Annual Net Assets for LivaNova PLC (1992–2025)
The table below shows the annual net assets of LivaNova PLC from 1992 to 2025. Also explore LIVN net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.20 Billion | -9.11% |
| 2024-12-31 | $1.32 Billion | +3.34% |
| 2023-12-31 | $1.28 Billion | +5.80% |
| 2022-12-31 | $1.21 Billion | -6.72% |
| 2021-12-31 | $1.29 Billion | +16.71% |
| 2020-12-31 | $1.11 Billion | -19.83% |
| 2019-12-31 | $1.38 Billion | -7.98% |
| 2018-12-31 | $1.50 Billion | -17.17% |
| 2017-12-31 | $1.82 Billion | +6.35% |
| 2016-12-31 | $1.71 Billion | -5.77% |
| 2015-12-31 | $1.81 Billion | +599.14% |
| 2014-12-31 | $259.10 Million | 0.00% |
| 2013-12-31 | $259.10 Million | +12.86% |
| 2012-12-31 | $229.57 Million | +25.13% |
| 2011-12-31 | $183.47 Million | +4.57% |
| 2010-12-31 | $175.45 Million | +1.26% |
| 2009-12-31 | $173.27 Million | +75.48% |
| 2008-12-31 | $98.74 Million | +530.74% |
| 2007-12-31 | $15.65 Million | +205.67% |
| 2006-12-31 | $-14.81 Million | -419.97% |
| 2005-12-31 | $4.63 Million | -93.88% |
| 2004-12-31 | $75.60 Million | +9.59% |
| 2003-12-31 | $68.98 Million | +2.32% |
| 2002-12-31 | $67.42 Million | +56.70% |
| 2001-12-31 | $43.02 Million | +0.37% |
| 2000-12-31 | $42.87 Million | +57.86% |
| 1999-12-31 | $27.15 Million | -18.70% |
| 1998-12-31 | $33.40 Million | -9.49% |
| 1997-12-31 | $36.90 Million | -24.39% |
| 1996-12-31 | $48.80 Million | +3153.33% |
| 1995-12-31 | $1.50 Million | -78.26% |
| 1994-12-31 | $6.90 Million | -62.70% |
| 1993-12-31 | $18.50 Million | -23.24% |
| 1992-12-31 | $24.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LivaNova PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 113112100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $2.35 Billion | 195.48% |
| Total Equity | $1.20 Billion | 100.00% |
LivaNova PLC Competitors by Market Cap
The table below lists competitors of LivaNova PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tauron Polska Energia S.A.
WAR:TPE
|
$4.21 Billion |
|
LG Uplus
KO:032640
|
$4.21 Billion |
|
PEPCO GROUP N.V. EO-01
F:8UX
|
$4.21 Billion |
|
Edenred SA
PA:EDEN
|
$4.21 Billion |
|
GRIFOLS ADR 1/2/EO-50
F:G0F
|
$4.21 Billion |
|
Zeta Global Holdings Corp
NYSE:ZETA
|
$4.21 Billion |
|
Andon Health Co Ltd
SHE:002432
|
$4.21 Billion |
|
Aya Gold & Silver Inc
TO:AYA
|
$4.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LivaNova PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,320,258,000 to 1,200,000,000, a change of -120,258,000 (-9.1%).
- Net loss of 242,500,000 reduced equity.
- Share repurchases of 4,430,000 reduced equity.
- Other comprehensive income increased equity by 80,170,000.
- Other factors increased equity by 46,502,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-242.50 Million | -20.21% |
| Share Repurchases | $4.43 Million | -0.37% |
| Other Comprehensive Income | $80.17 Million | +6.68% |
| Other Changes | $46.50 Million | +3.88% |
| Total Change | $- | -9.11% |
Book Value vs Market Value Analysis
This analysis compares LivaNova PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.95x to 3.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | $3.07 | $76.63 | x |
| 1993-12-31 | $2.07 | $76.63 | x |
| 1994-12-31 | $0.76 | $76.63 | x |
| 1995-12-31 | $0.16 | $76.63 | x |
| 1996-12-31 | $4.05 | $76.63 | x |
| 1997-12-31 | $2.29 | $76.63 | x |
| 1998-12-31 | $1.91 | $76.63 | x |
| 1999-12-31 | $1.50 | $76.63 | x |
| 2001-12-31 | $1.99 | $76.63 | x |
| 2002-12-31 | $3.06 | $76.63 | x |
| 2003-12-31 | $2.69 | $76.63 | x |
| 2004-12-31 | $3.15 | $76.63 | x |
| 2005-12-31 | $0.19 | $76.63 | x |
| 2006-12-31 | $-0.58 | $76.63 | x |
| 2007-12-31 | $0.59 | $76.63 | x |
| 2008-12-31 | $3.59 | $76.63 | x |
| 2009-12-31 | $6.04 | $76.63 | x |
| 2010-12-31 | $6.13 | $76.63 | x |
| 2011-12-31 | $6.48 | $76.63 | x |
| 2012-12-31 | $8.20 | $76.63 | x |
| 2013-12-31 | $9.43 | $76.63 | x |
| 2014-12-31 | $9.43 | $76.63 | x |
| 2015-12-31 | $68.03 | $76.63 | x |
| 2016-12-31 | $34.91 | $76.63 | x |
| 2017-12-31 | $37.43 | $76.63 | x |
| 2018-12-31 | $31.01 | $76.63 | x |
| 2019-12-31 | $28.62 | $76.63 | x |
| 2020-12-31 | $22.83 | $76.63 | x |
| 2021-12-31 | $25.57 | $76.63 | x |
| 2022-12-31 | $22.57 | $76.63 | x |
| 2023-12-31 | $23.57 | $76.63 | x |
| 2024-12-31 | $24.19 | $76.63 | x |
| 2025-12-31 | $22.02 | $76.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LivaNova PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.47%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 2.17x
- Recent ROE (-20.21%) is above the historical average (-68.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | -21.16% | -5100.00% | 0.00x | 1.05x | $-7.51 Million |
| 1993 | -31.89% | -1475.00% | 0.02x | 1.07x | $-7.75 Million |
| 1994 | -104.35% | -720.00% | 0.10x | 1.42x | $-7.89 Million |
| 1995 | -673.33% | -721.43% | 0.36x | 2.60x | $-10.25 Million |
| 1996 | -22.95% | -800.00% | 0.03x | 1.08x | $-16.08 Million |
| 1997 | -38.48% | -95.30% | 0.35x | 1.14x | $-17.89 Million |
| 1998 | -37.43% | -41.81% | 0.75x | 1.19x | $-15.84 Million |
| 1999 | -11.24% | -6.38% | 1.20x | 1.47x | $-5.77 Million |
| 2001 | -60.71% | -37.25% | 1.00x | 1.62x | $-30.42 Million |
| 2002 | 7.69% | 4.96% | 1.10x | 1.41x | $-1.56 Million |
| 2003 | 9.80% | 6.10% | 1.17x | 1.37x | $-138.54K |
| 2004 | -16.16% | -11.81% | 1.05x | 1.31x | $-19.78 Million |
| 2005 | -1275.83% | -47.85% | 0.81x | 32.90x | $-59.53 Million |
| 2006 | 0.00% | -39.08% | 0.96x | 0.00x | $-49.70 Million |
| 2007 | -66.02% | -8.52% | 1.15x | 6.72x | $-11.90 Million |
| 2008 | 27.06% | 18.61% | 0.98x | 1.48x | $16.85 Million |
| 2009 | 45.28% | 46.76% | 0.81x | 1.20x | $61.12 Million |
| 2010 | 26.63% | 24.53% | 0.90x | 1.21x | $29.18 Million |
| 2011 | 19.66% | 16.51% | 1.03x | 1.16x | $17.73 Million |
| 2012 | 20.19% | 18.23% | 0.96x | 1.15x | $23.40 Million |
| 2013 | 21.18% | 19.46% | 0.96x | 1.14x | $28.98 Million |
| 2014 | 21.18% | 19.46% | 0.96x | 1.14x | $28.98 Million |
| 2015 | 3.19% | 19.84% | 0.11x | 1.41x | $-123.30 Million |
| 2016 | -3.68% | -5.17% | 0.52x | 1.37x | $-233.49 Million |
| 2017 | -1.38% | -2.48% | 0.40x | 1.38x | $-206.63 Million |
| 2018 | -12.60% | -17.11% | 0.43x | 1.70x | $-339.77 Million |
| 2019 | -11.39% | -14.54% | 0.45x | 1.74x | $-296.01 Million |
| 2020 | -31.45% | -37.34% | 0.39x | 2.16x | $-459.75 Million |
| 2021 | -10.49% | -13.12% | 0.47x | 1.70x | $-265.28 Million |
| 2022 | -7.14% | -8.44% | 0.45x | 1.90x | $-207.01 Million |
| 2023 | 1.37% | 1.52% | 0.47x | 1.90x | $-110.22 Million |
| 2024 | 4.79% | 5.04% | 0.50x | 1.90x | $-68.79 Million |
| 2025 | -20.21% | -17.47% | 0.53x | 2.17x | $-362.50 Million |
Industry Comparison
This section compares LivaNova PLC's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,684,659,487
- Average return on equity (ROE) among peers: -78.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LivaNova PLC (LIVN) | $1.33 Billion | -21.16% | 0.99x | $4.21 Billion |
| Abbott Laboratories (ABT) | $24.53 Billion | 19.28% | 1.46x | $176.13 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $4.33 Million |
| Aethlon Medical Inc (AEMD) | $2.37K | -64.62% | 0.15x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $763.79 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $4.29 Million | -149.07% | 0.49x | $4.45 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $1.11 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $3.90 Million |
| Artivion Inc (AORT) | $79.80 Million | -34.79% | 0.33x | $1.10 Billion |
| Apyx Medical Inc (APYX) | $87.77 Million | 72.93% | 0.09x | $122.16 Million |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessor… Read more